^
    No biomarker
    Multiple Myeloma
    ALLO-715
    Sensitive
    :
    B
    Allogene Therapeutics Press Release - 2wk
    CD20 underexpression
    Multiple Myeloma
    lenalidomide
    Resistant
    :
    D
    Onco Targets Ther - 2wk
    CD20 underexpression
    Multiple Myeloma
    elotuzumab
    Resistant
    :
    D
    Onco Targets Ther - 2wk
    GPRC5D overexpression
    Multiple Myeloma
    JNJ-64407564
    Sensitive
    :
    D
    Blood Adv - 2wk
    No biomarker
    Multiple Myeloma
    isatuximab-irfc
    Sensitive
    :
    A1
    Sanofi Press Release - 3wk
    PPP1R15B overexpression
    Multiple Myeloma
    salubrinal
    Sensitive
    :
    D
    CSI-FCS 2020 - 3wk
    No biomarker
    Multiple Myeloma
    pomalidomide + elotuzumab
    Sensitive
    :
    A1
    No biomarker
    Multiple Myeloma
    carfilzomib
    Sensitive
    :
    A1
    No biomarker
    Multiple Myeloma
    bortezomib + panobinostat
    Sensitive
    :
    A1
    No biomarker
    Multiple Myeloma
    bortezomib + pegylated liposomal doxorubicin
    Sensitive
    :
    A1
    No biomarker
    Multiple Myeloma
    bortezomib
    Sensitive
    :
    A1
    No biomarker
    Multiple Myeloma
    SVd
    Sensitive
    :
    A1
    No biomarker
    Multiple Myeloma
    pomalidomide
    Sensitive
    :
    A1
    No biomarker
    Multiple Myeloma
    thalidomide
    Sensitive
    :
    A1
    No biomarker
    Multiple Myeloma
    isatuximab-irfc
    Sensitive
    :
    A1
    No biomarker
    Multiple Myeloma
    prednisone + thalidomide + melphalan
    Sensitive
    :
    A1
    No biomarker
    Multiple Myeloma
    lenalidomide + daratumumab/hyaluronidase
    Sensitive
    :
    A1
    No biomarker
    Multiple Myeloma
    lenalidomide + elotuzumab
    Sensitive
    :
    A1
    No biomarker
    Multiple Myeloma
    lenalidomide + daratumumab
    Sensitive
    :
    A1
    No biomarker
    Multiple Myeloma
    selinexor
    Sensitive
    :
    A1
    No biomarker
    Multiple Myeloma
    lenalidomide + ixazomib
    Sensitive
    :
    A1
    No biomarker
    Multiple Myeloma
    daratumumab/hyaluronidase
    Sensitive
    :
    A1
    No biomarker
    Multiple Myeloma
    bortezomib
    Sensitive
    :
    A1
    No biomarker
    Multiple Myeloma
    lenalidomide
    Sensitive
    :
    A1
    No biomarker
    Multiple Myeloma
    VTD
    Sensitive
    :
    A1
    No biomarker
    Multiple Myeloma
    belantamab mafodotin
    Sensitive
    :
    A1
    No biomarker
    Multiple Myeloma
    denosumab
    Sensitive
    :
    A1
    No biomarker
    Multiple Myeloma
    melphalan flufenamide
    Sensitive
    :
    A1
    No biomarker
    Multiple Myeloma
    pomalidomide + isatuximab-irfc
    Sensitive
    :
    A1
    No biomarker
    Multiple Myeloma
    lenalidomide + carfilzomib
    Sensitive
    :
    A1
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES